Publikationen in Zusammenarbeit mit Forschern von Kiel University (39)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Artificial Intelligence and Radiotherapy: Impact on Radiotherapy Workflow and Clinical Example

    Personalized Medicine Meets Artificial Intelligence: beyond “Hype, towards the Metaverse (Springer International Publishing), pp. 145-157

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria

    Allergy, Asthma and Immunology Research, Vol. 13, Núm. 3

  2. Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

    Modern Pathology, Vol. 34, Núm. 1, pp. 59-69

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Fenfluramine for Treatment-Resistant Seizures in Patients with Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial

    JAMA Neurology, Vol. 77, Núm. 3, pp. 300-308

2019

  1. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 12, pp. 2427-2436

  2. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 11, pp. 301-309

2018

  1. Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia

    Leukemia, Vol. 32, Núm. 4, pp. 874-881

2016

  1. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

    Nature Communications, Vol. 7

  2. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

    The Lancet Haematology, Vol. 3, Núm. 11, pp. e506-e515

2015

  1. Melanoma early detection and awareness: How countries developing melanoma awareness programs could benefit from melanoma-proficient countries

    American Journal of Therapeutics

  2. Treatment algorithms in stage IV melanoma

    American Journal of Therapeutics

  3. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers

    Genome Research, Vol. 25, Núm. 4, pp. 478-487

  4. Whole-genome fingerprint of the DNA methylome during human B cell differentiation

    Nature Genetics, Vol. 47, Núm. 7, pp. 746-756

2014

  1. Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels

    Journal of Hematology and Oncology, Vol. 7, Núm. 1

  2. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206

2013

  1. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma

    Journal of Clinical Oncology

2012

  1. A DNA methylation fingerprint of 1628 human samples

    Genome Research, Vol. 22, Núm. 2, pp. 407-419